Contents

15 Pneumococcal disease

References

  1. Garcia-Rodriguez JA, Fresnadillo Martinez MJ. 2002. Dynamics of nasopharyngeal colonization by potential respiratory pathogens. Journal of Antimicrobial Chemotherapy 50(Suppl S2): 59–73.
  2. Singh KP, Voolmann T, Lang SD. 1992. Pneumococcal bacteraemia in South Auckland. New Zealand Medical Journal 102(943): 394–5.
  3. Voss L, Lennon D. 1994. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand. Pediatric Infectious Disease Journal 13(10): 873–8.
  4. Heffernan H, Martin DR, Woodhouse RE, et al. 2008. Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance. Epidemiology and Infection 136(3): 352–9.
  5. Heffernan H, Morgan J, Woodhouse R, et al. 2010. Invasive Pneumococcal Disease in New Zealand, 2009. URL: https://surv.esr.cri.nz/PDF_surveillance/IPD/2009/2009AnnualIPDRpt.pdf
  6. Lim E, Heffernan H. 2013. Invasive Pneumococcal Disease in New Zealand, 2012. URL: www.surv.esr.cri.nz/PDF_surveillance/IPD/2012/2012AnnualIPDRpt.pdf (accessed 23 September 2013).
  7. Borman A, Heffernan, H. 2014. Invasive Pneumococcal Disease Quarterly Report: October–December 2013. URL: www.surv.esr.cri.nz/PDF_surveillance/IPD/2013/2013Q2_IPDReport.pdf (accessed 31 January 2014).
  8. Lucero MG, Dulalia VE, Nillos LT, et al. 2009. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age [Review]. Cochrane Database of Systematic Reviews. Issue 4, Art. No. CD004977. DOI: 10.1002/14651858.CD004977.pub2 (accessed 25 November 2013).
  9. Fitzwater SP, Chandran A, Santosham M, et al. 2012. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 31(5). DOI: 10.1097/INF.0b013e31824de9f6 (accessed 26 November 2013).
  10. Taylor S, Marchisio P, Vergison A, et al. 2012. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clinical Infectious Diseases 54(12). DOI: 10.1093/cid/cis292 (accessed 26 November 2013).
  11. Vogel AM, Trenholme AA, Stewart JM, et al. 2013. Impact of pneumococcal vaccine on hospital admission with lower respiratory infection in children resident in South Auckland, New Zealand. New Zealand Medical Journal 126(1378): 26–35.
  12. Petousis-Harris H. 2013. Pneumococcal disease in New Zealand and prevailing inequalities: the tip of the lower respiratory infection iceberg. New Zealand Medical Journal 126(1378): 9–11.
  13. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. Morbidity and Mortality Weekly Report 54(36). URL: www.cdc.gov/mmwr/PDF/wk/mm5436.pdf (accessed 16 January 2014).
  14. Griffin MR, Zhu Y, Moore MR, et al. 2013. US hospitalizations for pneumonia after a decade of pneumococcal vaccination. New England Journal of Medicine 369(17). URL: www.nejm.org/doi/pdf/10.1056/NEJMoa1209165 (accessed 16 January 2014).
  15. Pilishvili T, Lexau C, Farley MM, et al. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 201(1): 32–41.
  16. Miller E, Andrews NJ, Waight PA, et al. 2011. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. The Lancet Infectious Diseases 11(10). DOI: 10.1016/S1473-3099(11)70090-1 (accessed 30 October 2012).
  17. Elberse KEM, van der Heide HGJ, Witteveen S, et al. 2012. Changes in the composition of the pneumococcal population and in IPD incidence in the Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine 30(52): 7644–51.
  18. Vestrheim DF, Hoiby EA, Bergsaker MR, et al. 2010. Indirect effect of conjugate pneumococcal vaccination in a 2 1 dose schedule. Vaccine 28(10): 2214–21.
  19. Ingels H, Rasmussen J, Andersen PH, et al. 2012. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine 30(26): 3944–50.
  20. Simonsen L, Taylor RJ, Young-Xu Y, et al. 2011. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2(1). DOI: 10.1128/mBio.00309-10 (accessed 20 November 2012).
  21. Steens A, Riise Bergsaker MA, Aaberge IS, et al. 2013. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 31(52): 6232–8.
  22. Demczuk WHB, Martin I, Griffith A, et al. 2013. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine 2010–2012. Canadian Journal of Microbiology 59(12): 778–88.
  23. Kyaw MH, Lynfield R, Schaffner W, et al. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. New England Journal of Medicine 354(14): 1455–63.
  24. Gadzinowski J, Albrecht P, Hasiec B, et al. 2011. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13 valent pneumococcal conjugate vaccine. Vaccine 29(16): 2947–55.
  25. Snape MD, Klinger CL, Daniels ED, et al. 2010. Immunogenicity and reactogenicity of a 13-valent pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatric Infectious Disease Journal 29(12). DOI: 10.1097/INF.0b013e3181faa6be (accessed 26 November 2013).
  26. Yeh SH, Gurtman A, Hurley DC, et al. 2010. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 126(3). DOI: 10.1542/peds.2009-3027 (accessed 26 November 2013).
  27. Bryant KA, Block SL, Baker SA, et al. 2010. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 125(5): 866–75.
  28. Dagan R, Patterson S, Juergens C, et al. 2013. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clinical Infectious Diseases 57(7). DOI: 10.1093/cid/cit428 (accessed 18 September 2013).
  29. Gounder PP, Bruce MG, Bruden DJT, et al. 2013. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae – Alaska, 2008–2012. Journal of Infectious Diseases. DOI: 10.1093/infdis/jit642 (accessed 20 January 2014).
  30. Zuccotti G, Mameli C, Daprai L, et al. 2014. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine 32(5): 527–34.
  31. Cohen R, Levy C, Bingen E, et al. 2012. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatric Infectious Disease Journal 31(3): 297–301.
  32. Singleton R, Wenger J, Klejka JA, et al. 2012. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatric Infectious Disease Journal 32(3): 257–63.
  33. Miller E, Andrews NJ, Waight PA, et al. 2011. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29(49): 9127–31.
  34. Kaplan SL, Barson WJ, Ling Lin P, et al. 2013. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 32(3): 203–7.
  35. Martinelli D, Pedalino B, Cappelli MG, et al. 2014. Towards the 13-valent pneumococcal universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010–2013. Human Vaccines and Immunotherapeutics 10(1): 1–7.
  36. Marom T, Tan A, Wilkinson GS, et al. 2014. Trends in otitis media-related health care use in the United States, 2001–2011. JAMA Pediatrics 168(1). DOI: 10.1001/jamapediatrics.2013.3924 (accessed 20 January 2014).
  37. Frenck R, Thompson A, Senders S, et al. 2014. 13-valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 33(2): 183–9.
  38. Centers for Disease Control and Prevention. 2013. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 62(25). URL: http://www.cdc.gov/mmwr/pdf/wk/mm6225.pdf (accessed 27 January 2014).
  39. Jackson L, Gurtman A, van Cleeff M, et al. 2013. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults. Vaccine 31(35): 3577–84.
  40. Jackson L, Gurtman A, Rice K, et al. 2013. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 31(35): 3585–93.
  41. Jackson LA GA, van Cleef M, et al. 2013. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31(35): 3594–602.
  42. Huss A, Scott P, Stuck AE, et al. 2009. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Canadian Medical Association Journal 180(1): 48–58.
  43. Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, et al. 2010. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infectious Diseases 10(73). URL: www.biomedcentral.com/1471-2334/10/73 (accessed 30 October 2012).
  44. Cadeddu C, De Waure C, Gualano MR, et al. 2012. 23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective? Journal of Preventive Medicine and Hygiene 53(2): 101–3.
  45. Ministry of Health. 2012. National Guidelines for Vaccine Storage and Distribution. URL: www.health.govt.nz/publication/national-guidelines-vaccine-storage-and-distribution-2012.
  46. Cook IF, Pond D, Hartel G. 2007. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 25(25): 4757–74.
  47. GlaxoSmithKline NZ Ltd. 2014. Infanrix-hexa New Zealand Data Sheet. URL: http://www.medsafe.govt.nz/profs/datasheet/I/Infanrixhexainj.pdf (accessed 22 May 2015).
  48. Knuf M, Habermehl P, Cimino C, et al. 2006. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24(22):4727–36.
  49. Olivier C, Belohradsky B, Stojanov S, et al. 2008. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa–IPV–HBV–Hib combination vaccine in healthy infants. Vaccine 26(25): 3142–52.
  50. Kieninger D, Kueper K, Steul K, et al. 2010. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28(25): 4192–203.
  51. Esposito S, Tansey S, Thompson A, et al. 2010. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clinical and Vaccine Immunology (17)6: 1017–26.
  52. Tseng HF, Smith N, Sy LS, et al. 2011. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 29(20): 3628–32.
  53. Centers for Disease Control and Prevention. 2010. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Morbidity and Mortality Weekly Report 59(34). URL: www.cdc.gov/mmwr/pdf/wk/mm5934.pdf
  54. Jackson LA. 2013. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines: Elsevier Saunders.
  55. Lee J, Robinson JL, Spady DW. 2006. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. BMC Pediatrics 20(6). DOI: 10.1186/1471-2431-6-20 (accessed 11 October 2013).
  56. Thompson A, Gurtman A, Patterson S, et al. 2013. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: Meta-analysis of 13 clinical trials in 9 countries. Vaccine 31(45): 5289–95.
  57. Bentley DW, Ita K, Moon D, et al. 1981. Pneumococcal vaccine in the institutional elderly: design of a non randomized trial and preliminary results. Reviews of Infectious Diseases 3(Suppl): 571.
  58. Rodriguez R, Dyer PD. 1995. Safety of pneumococcal revaccination. Journal of General Internal Medicine 10(9): 511–12
  59. Mufson MA, Hughey DF, Turner CE, et al. 1991. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 9(6): 403–7.
  60. Snow R, Babish JD, McBean AM. 1995. Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? Public Health Reports 110(6): 720–5.
  61. Tse A, Tseng HF, Greene SK, et al. 2012. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010–2011. Vaccine 30(11): 2024–31.
  62. Schwarz TF, Flamaing J, Rumke HC, et al. 2011. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 29(32): 5195–202.
  63. Gable CB, Holzer SS, Englehart L, et al. 1990. Pneumococcal vaccine: efficacy and associated cost savings. Journal of the American Medical Association 264(22): 2910–15.